• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    6/14/21 4:31:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email
    SC 13D/A 1 d157510dsc13da.htm SC 13D/A #5 SC 13D/A #5

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Danaher Corporation

    (Name of Issuer)

    Common Stock, par value $.01 per share

    (Title of Class of Securities)

    23585110

    (CUSIP Number)

    Joseph O. Bunting, III

    2200 Pennsylvania Avenue, N.W., Suite 800W

    Washington, DC 20037-1701

    (202) 419-7645

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 10, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     

     


    CUSIP No. 23585110

      1.    

      Names of Reporting Persons.

      I.R.S. Identification Nos. of above persons (entities only).

     

      Steven M. Rales

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      USA

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      43,454,958(1)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      43,454,958(1)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      43,454,958 (1)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      6.1%(2)

    14.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    1

    Includes 250,405 shares of common stock underlying 50,000 shares of the Company’s Series B Mandatory Convertible Preferred Stock beneficially owned by Steven M. Rales, calculated at the conversion rate in effect as of the date of this report. See Item 5 below for additional information.

    2

    Based on 713,278,866 shares of the Company’s common stock outstanding as of April 16, 2021, as reported in the Company’s Quarterly Report on Form 10-Q filed on April 22, 2021, and assuming conversion of all of the Series B Mandatory Convertible Preferred Stock beneficially owned by the Reporting Person.


    Introductory Statement

    This Amendment No. 5 (this “Amendment No. 5”) to the Statement on Schedule 13D (the “Statement”) relates to the common stock, par value $.01 per share of Danaher Corporation, a corporation organized under the laws of the state of Delaware (the “Company”). This Amendment No. 5 amends and supplements (i) the Statement originally filed on March 30, 2007 with the Securities and Exchange Commission (the “Commission”) by Steven M. Rales, (ii) Amendment No. 1 to the Statement filed on July 31, 2009, (iii) Amendment No. 2 to the Statement filed on June 30, 2011, (iv) the Amendment No. 3 to the Statement filed on October 25, 2012 and (v) the Amendment No. 4 to the Statement filed on May 14, 2020. Unless otherwise defined herein, capitalized terms used herein shall have the meanings ascribed thereto in the initial Schedule 13D, Amendment No. 1 or Amendment No. 2, Amendment No. 3, or Amendment No. 4, as applicable.

    Item 4. Purpose of Transaction

    Item 4 of the Statement is hereby supplemented as follows:

    On June 10, 2021, the Reporting Person and Mitchell P. Rales each transferred for no consideration 8,000,000 shares of the Company’s common stock to Capital Yield Corporation (“CYC”), a corporation of which each of the Reporting Person and Mitchell P. Rales is a 50% stockholder. On June 11, 2021, CYC gifted 6,100,000 shares of the Company’s common stock to a charitable foundation affiliated with the Reporting Person and 6,100,000 shares of the Company’s common stock to a charitable foundation affiliated with Mitchell P. Rales. On June 11, 2021, the remaining 3,800,000 shares of the Company’s common stock held by CYC were distributed to the Reporting Person and Mitchell P. Rales on a pro rata basis based on their respective ownership interests in CYC.

    Item 5. Interest in Securities of the Issuer

    Item 5 of the Statement is hereby amended as follows:

    As of the date hereof, Steven M. Rales is the beneficial owner of 43,454,958 shares of common stock representing approximately 6.1% of the approximately 713,278,866 shares outstanding as of April 16 2021, as disclosed in the Company’s Quarterly Report on Form 10-Q filed on April 22, 2021, and assuming conversion of all of the Series B Mandatory Convertible Preferred Stock


    beneficially owned by the Reporting Person. The Reporting Person’s beneficial ownership consists of 31,000,000 shares owned by limited liability companies of which the Reporting Person is the trustee of the sole member, 19,313 shares attributable to the Reporting Person’s 401(k) account, 2,096,716 shares held through a revocable trust of which the Reporting Person is trustee, 3,818,024 held through grantor retained annuity trusts of which the Reporting Person is trustee and sole annuitant, and 6,270,500 shares owned by a charitable foundation of which the Reporting Person is sole director.

    The Reporting Person’s beneficial ownership also consists of approximately 125,202.5 shares of common stock underlying 25,000 shares of the Company’s Series B Mandatory Convertible Preferred Stock held through a revocable trust of which the Reporting Person is trustee, and approximately 125,202.5 shares of common stock underlying the 25,000 shares of the Company’s Series B Mandatory Convertible Preferred Stock owned by a charitable foundation of which the Reporting Person is sole director, in each case calculated based on the conversion rate in effect as of the date hereof. At any time prior to April 15, 2023, the Reporting Person has the option to elect to convert the shares of the Series B Mandatory Convertible Preferred Stock in whole or in part into shares of the Company’s common stock at the minimum conversion rate of 5.0081 shares of the Company’s common stock per share of Series B Mandatory Convertible Preferred Stock. In addition, the Series B Mandatory Preferred Stock will convert into shares of the Company’s common stock on the second business day immediately following the last trading day of the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately preceding April 15, 2023 (the “mandatory conversion date”). Upon conversion on the mandatory conversion date, the conversion rate for each share of the Series B Mandatory Convertible Preferred Stock will be not more than 6.1349 shares of common stock and not less than 5.0081 shares of common stock, with the exact conversion rate depending on the applicable market value of the common stock.

    The Reporting Person disclaims beneficial ownership of all of the other shares of common stock that are owned directly or indirectly by Mitchell P. Rales.

    All of the shares of the Company’s common stock held by the limited liability companies of which the Reporting Person is the trustee of the sole member are pledged to secure lines of credit with certain banks and each of these entities and the Reporting Person is in compliance with the terms of these lines of credit.

    The information in Item 4 is incorporated by reference herein.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    June 14, 2021

    Date

    /s/ Steven M. Rales

    Signature

    Steven M. Rales

    Name/Title

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

    Get the next $DHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    12/9/2025$265.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Danaher Schedules First Quarter 2026 Earnings Conference Call

    WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You ca

    3/20/26 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Announces Quarterly Dividend

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and

    2/24/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher to Present at TD Cowen Health Care Conference

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 3, 2025 at 1:50 p.m. ET. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health

    2/24/26 4:05:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    SEC Filings

    View All

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-K filed by Danaher Corporation

    10-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/24/26 4:36:41 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Leadership Update

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/17/26 8:08:12 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/10/26 4:22:59 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Goldman initiated coverage on Danaher with a new price target

    Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00

    12/9/25 8:43:56 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Morgan Stanley initiated coverage on Danaher with a new price target

    Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00

    12/2/25 8:25:25 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Danaher from Buy to Neutral and set a new price target of $220.00

    10/8/25 8:23:31 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Executive Vice President Riley Christopher Paul was granted 6,172 shares and covered exercise/tax liability with 1,115 shares, increasing direct ownership by 33% to 20,400 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:02 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SVP-Chief Legal Officer Leiken Jonathan was granted 2,374 shares, increasing direct ownership by 23% to 12,546 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:26 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Executive Vice President Mcgrew Matthew was granted 5,935 shares, increasing direct ownership by 28% to 26,825 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:22 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Jonathan Leiken as General Counsel

    WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca

    7/31/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Financials

    Live finance-specific insights

    View All

    Danaher Schedules First Quarter 2026 Earnings Conference Call

    WASHINGTON, March 20, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2026 on Tuesday, April 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.You ca

    3/20/26 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Announces Quarterly Dividend

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and

    2/24/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/23 11:16:32 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/22 3:43:35 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

    11/2/21 9:29:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials